Susquehanna Fundamental Investments’s ADC Therapeutics ADCT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$32.7K	Buy	+10,355	New	+$41.2K	﹤0.01%	917
2022 Q1	$425K	Sell	28,949 -3,051	-10%	-$48.4K	0.01%	1135
2021 Q4	$646K	Sell	32,000 -11,258	-26%	-$271K	0.02%	818
2021 Q3	$1.18M	Buy	43,258 +241	+0.6%	+$6.17K	0.02%	801
2021 Q2	$1.05M	Buy	+43,017	New	+$998K	0.02%	840
2021 Q1	–	Sell	-8,252	Closed	-$264K	–	1517
2020 Q4	$264K	Sell	8,252 -23,978	-74%	-$786K	﹤0.01%	1288
2020 Q3	$1.06M	Buy	32,230 +6,352	+25%	+$275K	0.03%	621
2020 Q2	$1.21M	Buy	+25,878	New	+$982K	0.06%	407

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Susquehanna Fundamental Investments's ADCT Position: Q2 2024 in Review

Susquehanna Fundamental Investments opened a new position in ADC Therapeutics (ADCT) in Q2 2024: 10,355 shares worth $32.7K. The stake represents ﹤0.01% of the portfolio and ranks #917 among its holdings. This is a return to the name: Susquehanna Fundamental Investments previously reported a position in ADCT as recently as Q1 2022.

Susquehanna Fundamental Investments first reported a position in ADCT in Q2 2020 and has held it in 8 quarters since. The position peaked at $1.21M in Q2 2020. 74 funds tracked by Wall St. Rank hold ADCT as of Q2 2024.

Susquehanna Fundamental Investments held 10,355 shares of ADC Therapeutics worth $32.7K as of Q2 2024.
ADC Therapeutics was a new Susquehanna Fundamental Investments position in Q2 2024.
ADC Therapeutics made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q2 2024, its #917 holding.
Susquehanna Fundamental Investments first reported a position in ADC Therapeutics in Q2 2020 and has held it in 8 quarters since.
Susquehanna Fundamental Investments's ADC Therapeutics position peaked at $1.21M in Q2 2020.
74 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2024.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2024, filed 15 Aug 2024.